MacroGenics Closes $30.5M Series B VC Round

MacroGenics, a Rockville, Md.-based firm that develops therapeutic antibodies for use in the treatment of various cancers and inflammatory diseases, has collected $30.5 million in a Series B round of private-equity financing, the company said last week.

MacroGenics lists Institute for Systems Biology co-founders Lee Hood, Alan Aderem, and Ruedi Aebersold among its founders, as well as Jeffrey Ravetch from Rockefeller University.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.